The Employees’ State Insurance Corporation (ESIC), on October 29, 2026, informed all ESIC medical institutions and State ESI Schemes regarding the declaration of Telmisign AM Tablets as “Not of Standard Quality” (NSQ). The drug, manufactured by M/s Phytochemical Industries, contains Telmisartan 40 mg and Amlodipine 5 mg. The sample was tested by the Government Analyst, Jalukbari, Guwahati, under Report No. SDTL/L/AK/2026/1582 dated October 14, 2026, and failed to conform to Indian Pharmacopoeia (I.P.) requirements with respect to the dissolution test.
ESIC has directed the concerned medical stores to immediately withdraw the affected batch from substores, dispensaries and patient-care areas and discontinue its use. The vendor must be asked to replace the stock with another batch within 15 days, failing which the stock must be collected and returned, or other action, including risk purchase, initiated, with recovery of testing costs, if any, from the vendor. Institutions must also initiate action under the relevant clauses of the applicable DG-ESIC Tender Enquiry/Rate Contract and maintain records of the action taken.
The instructions require immediate compliance by all concerned ESIC institutions. The affected batch must not be used, and withdrawal, replacement or recovery proceedings must be initiated and documented in accordance with the prescribed directions.
[ESIC File No. U-25/12/NSQ/2021-MedV (E-1119), NSQ-13/2026]
